New hope for hard-to-treat lymphoma: targeted drug combo enters phase 2 trial
NCT ID NCT04989621
First seen Apr 24, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This study is testing whether a combination of two drugs (orelabrutinib and rituximab) followed by long-term orelabrutinib can shrink tumors or slow disease in people whose follicular lymphoma has come back or stopped responding to prior treatment. About 32 adults will receive the treatment, and researchers will measure how many patients respond and how long the benefit lasts. Because patients continue maintenance therapy indefinitely, this is a disease-control approach, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong General Hospital
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,
NOT_YET_RECRUITINGGuangzhou, Guangdong, 51000, China
Contact
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,
RECRUITINGGuangzhou, Guangdong, 51000, China
Contact
Conditions
Explore the condition pages connected to this study.